Navigation Links
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
Date:2/6/2008

ency (EMEA) for Cimzia(R) in the treatment of RA is ongoing, with filing planned in the first half of 2008.

In September 2007, Cimzia(R) was approved in Switzerland for the treatment of Crohn's disease and it was launched in January 2008.

About Rheumatoid Arthritis

RA is a progressive autoimmune disease that causes chronic inflammation of the joints. It is estimated that five million people suffer from RA globally, with 0.3 percent to 1 percent of the population in industrialized countries suffering from the disease. Women are three times more likely to be affected than men. Although it can affect people of all ages, the onset of RA usually occurs between the ages of 35-55.

Traditional treatments for RA include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs), with biological therapies a more recent addition.

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on Euronext Brussels.

UCB Forward-Looking Statement

This news release contains forward-looking statements that involve risks and uncertainties, including statements with respect to the development and commercialization of certolizumab pegol. Among the factors that could cause actual results to differ materially from those indicated by such forward- looking statements are: the results of research, development and clinical trial
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
2. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
5. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
11. AEterna Zentaris Announces Outcome of Managements Strategic Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Unraveling life’s ... together. The Archer Family purchased a DNA ... DNA, but ended up with a lifetime of memories, ... within the family members’ DNA genuinely brought the family ... to search deeper into genetic history and prior to ...
(Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... Follow, THE WOODLANDS, Texas, Feb. 20 Lexicon,Pharmaceuticals, ... quarter and,year end 2007 financial results on Thursday, March ... hold a conference call to,discuss its clinical development progress, ... 5:00 p.m. Eastern Time on March 6, 2008., ...
... ... 2006, to RMB17.9 ... to RMB180.2 ... ...
... Unprecedented ... Accuracy, PITTSBURGH, Feb. ... has been published in,January 2008 edition of the Federal Register as a ... known as RCRA (Resource,Conservation and Recovery Act). This updated version of the ...
Cached Biology Technology:Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 23SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 16Newly Published EPA RCRA Method 6800 Supports AIT Technology 2
(Date:7/10/2014)... July 3, 2014 According to ... Type (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, ... Security and Banking & Finance), and Geography - Global ... MarketsandMarkets, the global Fingerprint Sensors Market is projected to ... CAGR of 16.8% from 2014 to 2020. ...
(Date:7/10/2014)... GOTHENBURG, Sweden , July 7, 2014 ... won its first major design win (DW). A Chinese Top ... with the planned start of mass production in October 2014. ... with a Chinese Top 5 smartphone OEM, which has a ... 2014 and a target sales volume for this phone of ...
(Date:7/10/2014)... July 8, 2014 Fingerprint ... new design win (DW). An Asian OEM has selected FPC1021 ... production start in August 2014.   FPC is ... which has a planned date for start of mass production ... order of SEK 5M, for delivery in the first half ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... Inc.,(OTC Bulletin Board: BKYI), a leader in wireless public ... the,company,s Chief Executive Officer, Michael DePasquale, is featured in ... interview gives viewers an overview of the company, and ... To view the clip in its entirety, ...
... of its kind in the United States, researchers have ... outperforms current biofuels sources by a lot. Using ... U.S. could significantly reduce the acreage dedicated to biofuels ... The new findings, from researchers at the University ...
... Berkeley, virologist and an assistant professor in the Department of ... Foundation grant, an award given to innovative young scientists in ... up to $1 million over five years, will go to ... a tool to study the inner workings of human cells. ...
Cached Biology News:[video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.net's 3-Minute Press Show 2Miscanthus can meet US biofuels goal using less land than corn or switchgrass 2Miscanthus can meet US biofuels goal using less land than corn or switchgrass 3UC Berkeley virologist named Keck Distinguished Young Scholar 2
AedestaTM Animal Organ/Tissue Perfusion Soln....
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
... complementary RNA Spikes for the normalization and ... array printing and for protocol assessment and ... hybridization stringency and background. Normalize Cy3 and ... Oligo Spots, and complementary RNA Spikes for ...
Biology Products: